Quiz

Article

NeurologyLive® Brain Games: September 15, 2024

Author(s):

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on non-relapsing secondary progressive multiple sclerosis.

Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical and historical neurology topics, written by physicians, clinicians, and experts in the fields of neurological care and advocacy.

Test your mettle each week with 3 questions that cover a variety of aspects in the field of neurology, with a focus on dementia and Alzheimer disease, epilepsy and seizure disorders, headache and migraine, movement disorders, multiple sclerosis, neuromuscular disorders, sleep disorders, and stroke and cerebrovascular disease.

This week's questions include the theme of non-relapsing secondary progressive multiple sclerosis.

Click here to check out the prior iterations of Brain Games.

Interested in submitting quiz questions? Contact our editor, Marco Meglio, via email: mmeglio@neurologylive.com.

Which of the following is considered a primary characteristic of non-relapsing secondary progressive multiple sclerosis?


What is the most common first-line disease-modifying therapy (DMT) used for non-relapsing secondary progressive multiple sclerosis (SPMS)?


Which of the following symptoms is commonly seen in patients with non-relapsing secondary progressive multiple sclerosis (SPMS) but not typically in relapsing-remitting MS (RRMS)?


How did you do on this week's quiz? Let us know with a response to the poll below. Don't forget to share and compare your results with your friends!

How many questions did you get correct?

One
Two
Three

Related Videos
Mikael Cohen, MD
Robert J. Fox, MD; Andreas Muehler, MD, MBA
1 KOL is featured in this series.
1 KOL is featured in this series.
Wallace Brownlee, MBChB, PhD, FRACP
Sharon Hesterlee, PhD
© 2024 MJH Life Sciences

All rights reserved.